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Cytokines are key modulators of the immune system and also contribute to regulation of the ovarian cycle. In this study, Bender
MedSystems FlowCytomix technology was used to analyze follicular cytokines (proinﬂammatory: IL-1β, IL-6, IL-18, IFN-γ,I F N -
α,T N F - α, IL-12, and IL-23;, and anti-inﬂammatory: G-CSF), chemokines (MIP-1α,M I P - 1 β, MCP-1, RANTES, and IL-8), and
other biomarkers (sAPO-1/Fas, CD44(v6)) in 153 women undergoing in vitro fertilization (IVF). Cytokine origin was studied by
mRNAanalysisofgranulosacells.HigherfollicularMIP-1αandCD44(v6)werefoundtocorrelatewithpolycysticovarysyndrome,
IL-23, INF-γ,a n dT N F - α with endometriosis, higher CD44(v6) but lower IL-β and INF-α correlated with tubal factor infertility,
and lower levels of IL-18 and CD44(v6) characterized unexplained infertility. IL-12 positively correlated with oocyte fertilization
and embryo development, while increased IL-18, IL-8, and MIP-1β were associated with successful IVF-induced pregnancy.
1.Introduction
Immunological abnormalities have been implicated in
female reproductive failure, but whether these represent a
cause or eﬀect is unknown [1, 2]. According to our previous
research, cellular and, particularly, humoral autoimmuno-
logic perturbations are responsible for development of
female infertility. Disturbances in the humoral immune
system may lead to impairments in ovarian folliculogenesis
[3–5], a long and complex process in which both the
endocrine and immune systems play signiﬁcant roles.
Cytokines, originally identiﬁed as products of immune
cells, are important mediators of immune responses. These
proteins are able to stimulate or inhibit cell growth, regulate
cell diﬀerentiation,inducecellchemotaxis,andmodulatethe
expression of other cytokines. However, recent research has
indicated that cytokines are synthesized by a broad range
of nonimmune cell types, including the normal ovarian
cells. Cytokine function in the ovary has been described as
promoting processes of follicular growth, steroidogenesis,
recruitmentandactivationofleukocytesnecessaryforovula-
tion and tissue remodelling during ovulation, luteinization,
and luteolysis [6].
To gain a more detailed understanding of the cytokines
involved in female fertility and their role in pregnancy
outcome, we assessed 16 diﬀerent follicular cytokines during
infertilitytreatment.Inparticular,weevaluatedthecytokines
for Th1/proinﬂammation (interleukin- (IL-) 1β,I L - 6 ,I L -
12, IL-18, IL-23, interferon (IFN)-γ,I F N - α,a n dt u m o r
necrosis factor-(TNF-) α) and anti-inﬂammation (granu-
locyte colony stimulating factor (G-CSF)), the principal
chemokines (macrophage inﬂammatory protein- (MIP-)
1α,M I P - 1 β, monocyte chemotactic protein- (MCP-) 1,
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(RANTES) and IL-8), and other biomarkers (soluble apop-
tosis antigen (sAPO)-1/Fas and CD44 variant isoform
CD44(v6)) secreted into the follicular ﬂuid. The cytokines
chosen for evaluation were shown in our previous study
to be appreciably expressed in follicular granulosa cells at
the mRNA level [7]; moreover, the importance of these
particular cytokines in ovarian function has been proposed
by others [8].
IL-1β, IL-6, and IL-18 are key mediators of inﬂammation
andmediatemanypathwaysofthenormalimmuneresponse
[9–11]. Human IFN-α comprises a family of extracellular
signalling proteins with demonstrated antiviral, antiprolif-
erating, and immunomodulatory activities [12]. The type
II interferon IFN-γ is another proinﬂammatory cytokine
and has been implicated in the development of a variety
of autoimmune diseases [13]. IL-12 regulates cell-mediated
immune responses. The p40 subunit of IL-12 is shared with
IL-23 and is essential for recruitment and activation of many
inﬂammatory cell types. Both of these cytokines interact
with the innate and adaptive immune systems [14]. TNF-
α, an acute phase protein, is critically involved in innate
immuneresponsescausedbypathogenexposure[15]butcan
also mediate noninfectious inﬂammatory processes such as
autoimmunity and cancer [16].
Among the chemokines examined in this study, IL-8
is a neutrophil-speciﬁc factor involved in inﬂammatory
processes and angiogenesis [17]. MIP-1α and MIP-1β are
known as CC chemokines, and both act as chemoattractants
forTcellsandmonocytestomediatebeneﬁcialinﬂammatory
processes, such as wound healing [18]. Meanwhile, MCP-1
and RANTES are potent chemoattractants of monocytes and
Tl y m p h o c y t e s[ 19].
The other biomarkers examined in this study are estab-
lished immunomodulators. G-CSF acts as a growth factor
for haematopoietic cells [20]. APO-1 regulates tissue ho-
meostasis by acting as the receptor for Fas ligand, the
binding of which triggers a signaling cascade that leads to
apoptosis inhibition [21]. And CD44(v6), a splice variant of
the CD44, is a transmembrane glycoprotein associated with
cell adhesion and has mostly been investigated in tumours
[22].
In recent decades, above-mentioned cytokines have
becomethesubjectofstudiesexaminingnormalmammalian
reproduction [23], which have indicated a signiﬁcant role
for these factors in supporting female fertility. Thus, we
carried out a simultaneous (multiplex) examination of these
cytokines and biomarkers in follicular ﬂuid of infertile
women in order to assess their eﬀects on oocyte and
embryo quality and on pregnancy outcome of in vitro
fertilization (IVF) treatment. The approach of cytokine
proﬁling using multiplex assays oﬀers a promising tool
for identifying condition-speciﬁc biomarker panels with
high accuracy [24]. We employed the Bender MedSystems
FlowCytomix platform, which uses antibody-coated autoﬂu-
orescent beads to simultaneously measure corresponding
analytes from small sample volumes and low concentrations
[24], facilitating time- and cost-eﬃcient high-throughput
screening. In addition, we sought to determine the origin of
the secreted cytokines by performing mRNA analysis from
two distinct follicular somatic cell populations: mural and
cumulus granulosa cells (MGC and CGC, resp.).
2.MaterialsandMethods
2.1. Patients. The Ethics Committee on Human Research of
the University of Tartu approved this study, and informed
consent was obtained from all patients. The study group
consisted of 153 women, aged 33.3 ± 4.5 years (mean ±
standard deviation), who underwent IVF at Nova Vita Clinic
between 2007 and 2010. IVF with intracytoplasmic sperm
injection (ICSI) was performed in all women in this cohort,
and the case was either male factor infertility or previous
oocyte fertilization failure. The causes of infertility were
distributedasfollows:malefactorinfertility(43.8%,n = 67),
tubal factor infertility (TFI; 28.8%, n = 44), polycystic ovary
syndrome (PCOS; 5.2%, n = 8), endometriosis (15.0%,
n = 23), unexplained infertility (4.6%, n = 7), and other
reasons (2.6%, n = 4).
Ovarian hormonal stimulation was conducted according
to a protocol of gonadotrophin-releasing hormone (GnRH)
antagonist (Cetrotide; Merck Serono, Geneva, Switzerland)
administered with recombinant follicle-stimulating hor-
mone(Gonal-F;MerckSeronoorPuregon,Schering-Plough,
Kenilworth, NJ, USA). ICSI was performed at 4–6h after
oocyte pickup (OPU), resulting in a 68.9% fertilization rate.
ICSI-derived embryos were cultured up to 48h, after which
good-quality embryos were identiﬁed by the presence of at
least four blastomeres and ≤20% fragmentation. The rate of
good-quality embryos was calculated as the proportion (%)
of good-quality embryos out of all fertilized oocytes. Two
embryos were chosen for transfer to the uterus, and 25.5%
of clinical pregnancies resulted per embryo transfer. Clinical
conﬁrmation of intrauterine pregnancy was made using an
ultrasound scan performed at the 6th or 7th week after
transference. Follicular ﬂuid samples from each individual
weretakenfromasinglefollicleonthedayofOPUandstored
at −80◦C until further use.
2.2. Flow Cytometry Analysis. Altogether, 16 biomarkers
(divided into two 8 plexes) were evaluated from the individ-
ual follicular ﬂuid samples by using a commercially available
FlowCytomix Human Basic Kit Assay (Bender MedSys-
tems, Vienna, Austria) and following the manufacturer’s
instructions. Quantitation measurements were performed
by ﬂow cytometer instrument FC 500 and accompanying
CXP Software (Beckman Coulter, Calif, USA). The ﬁrst
8 plex consisted of: IL-23, sAPO-1/Fas, MIP-1β,M I P - 1 α,
CD44(v6), IL-8, G-CSF, and RANTES. The second 8-plex
consisted of IL-12p70, IFN-γ,M C P - 1 ,I L - 6 ,I F N - α, IL-18,
Il-1β,a n dT N F - α. Samples were prepared for processing
by ﬁrst thawing follicular ﬂuids and centrifuging the whole
volume at 450g for 10min. The resulting supernatants
were used for analysis. FlowCytomix Pro 2.3 Software
was used to perform calculations (Bender MedSystems).
Standard curves for each biomarker were generated with
manufacturer-supplied reference analyte (pg/mL concentra-
tions). The concentration of a biomarker was calculated asClinical and Developmental Immunology 3
Table 1: List of primers used for real-time PCR analysis.
Gene Forward primer Reverse primer NCBI reference
G-CSF [25] GCTTGAGCCAACTCCATAGC CAGATGGTGGTGGCAAAGTC NM 001178147.1, NM 172220.2,
NM 172219.2, NM 000759.3
IL-23A [26] TGTTCCCCATATCCAGTG TCCTTTGCAAGCAGAACTGA NM 016584.2
IFN-γ TGATGGCTGAACTGTCGCCAGC CTGGGATGCTCTTCGACCTCGA NM 000619.2
MIP-1α TCAGAAGGACACGGGCAGCAGA TCAGCAGCAAGTGATGCAGAGAAC NM 002983.2
sAPO-1/Fas CCAAGTGCAAAGAGGAAGTGAAGAG TGGTTTTCCTTTCTGTGCTTTCTGC NM 152871.2
CD44(v6) GCTACCACAGCCTCAGCTCA ACCTCGTCCCATGGGGTGTGA NA∗
∗The forward primer was designed to cross the junction between exons 5 and 11, characteristic for only CD44(v6)-soluble splice isoform not described in
NCBI database.
meanﬂuorescentintensitydividedbysinglemedianstandard
curve.
2.3. Gene Expression Analysis. Gene expression studies of
the measured cytokines were performed by real-time PCR
of mRNA isolated from MGC and CGC from six patients.
MGC were obtained from follicular ﬂuid after OPU, and
CGC were collected 4h after OPU during oocyte denudation
with bovine type IV-S hyaluronidase (Sigma-Aldrich, St-
Louis, Mo, USA). The detailed isolation protocol has been
previously published [7]. For leukocyte elimination, the
MGC pool was incubated with CD45-coated magnetic beads
(Dynabeads; Invitrogen, Oslo, Norway) for an additional 1h
at 4◦C, followed by magnet-based cell sorting (DynaMag-
15; Invitrogen) according to the manufacturer’s protocol.
Total RNA was extracted, and real-time PCR analysis
was performed using either commercially available real-
time PCR arrays (products PAHS-011A and PAHS-021A;
SABiosciences, Frederick, Md, USA) or in-house designed
and synthesized primers when the desired transcripts were
not included in the kits or the quality of ampliﬁcation, and
melting curves were not satisfactory. Primers for Fas were
designed to exclusively detect the soluble isoform, and those
forCD44weredesignedtoamplifyonlyexon11(thevariable
region 6). All primer sequences used in this study are listed
in Table 1.
For double-stranded cDNA synthesis, 1μgo fh i g h -
quality total RNA was treated with DNase (Fermentas,
Burlington, ON, Canada) and reverse transcribed to cDNA
using the RT2 First Strand Kit (SABiosciences) according to
the manufacturer’s protocols. RT2 SYBR Green/ROX qPCR
Master Mix (SABiosciences) and cDNA template were added
to the array and product ampliﬁcation was performed on a
7500 real time PCR System (Applied Biosystems, Foster City,
Calif, USA). Those real-time PCR reactions using in-house
primers were performed using the Power SYBR Green PCR
Master Mix (Applied Biosystems) and the 7900HT real-time
PCR instrument (Applied Biosystems).
Results were analyzed with instrument-speciﬁc soft-
ware using the ΔΔCt relative quantiﬁcation method. Three
housekeeping genes were used for normalization of the
ampliﬁcation data: beta actin, glyceraldehyde-3-phosphate
dehydrogenase, and ribosomal protein RPL13A.
2.4.StatisticalAnalysis. TheR2.3.1ALanguageandEnviron-
ment (Free Software Foundation, Boston, Mass, USA) was
used to perform t-, Mann-Whitney U- and proportion tests
and adjusted simple regression analysis. A P value <0.05 was
considered as indicative of statistical signiﬁcance.
3. Results
Table 2 summarizes the clinical data and infertility treatment
parameters, while Table 3 lists detected concentrations of
the tested biomarkers. Figure 1 summarizes the main asso-
ciations observed between the clinical data and the levels
of follicular biomarkers, according to analysis by adjusted
regression models.
3.1. Associations between Infertility Cause and Levels of
BiomarkersinFollicularFluid. Patientscharacterizedbymale
factor infertility represented the reference group in simple
regression analysis, unless otherwise stated. Our results
indicated that women with TFI had lower concentrations of
IL-1β-adjusted r =− 12.6pg/mL, P = 0.037), and lower
IFN-α levels were also signiﬁcantly associated with TFI when
the status of current smoking was included in the model
(adjusted r =− 13.9pg/mL,P = 0.046).
PCOS patients were characterized by signiﬁcantly
higher follicular levels of CD44(v6) (age-adjusted r =
2072.7pg/mL, P = 0.010) and MIP-1α (adjusted for age,
cause of infertility, and follicular count in prestimulatory
ovary r = 3111.7pg/mL, P = 0.007). Women with
endometriosis presented with higher levels of IL-23 than
male factor infertility patients (adjusted by follicular number
prior to stimulation r = 157.1pg/mL,P = 0.025). Moreover,
when compared to TFI patients, women with endometriosis
had higher levels of follicular TNF-α (age-adjusted r =
2.6pg/mL, P = 0.047) and IFN-γ (adjusted by follicular
n u m b e rp r i o rt os t i m u l a t i o nr = 16.4pg/mL,P = 0.030). In
women with unexplained infertility, signiﬁcantly lower levels
of follicular CD44(v6) were measured, as compared to male
factor infertility patients (age-adjusted r =− 1888.4pg/mL,
P = 0.025). However, when compared to TFI patients, the
unexplained infertility patients also had lower levels of IL-18
(age-adjusted r =− 186.7pg/mL,P = 0.021).4 Clinical and Developmental Immunology
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Figure 1: Associations between biomarkers and infertility parameters. Red boxes indicate positive association, green boxes negative
association; empty boxes indicate no association found by adjusted regression analysis. Male factor infertility was chosen as a reference
group, but in cases marked with ∗. TFI was used as a reference. Abbreviations are as mentioned in the text.
Active smoking was associated with elevated follicular
CD44(v6) levels (adjusted for age and cause of infertility
r = 1227.8pg/mL,P = 0.019 versus never smokers group)
and sAPO-1/Fas levels (adjusted r = 464.9pg/mL,P = 0.031
versusnever-smokersgroup).Similarly,follicularIL-23levels
were higher in women who reported history of smoking or
current smoking, as compared to never-smokers, regardless
of age or cause of infertility (adjusted r = 107.6pg/mL,
P = 0.043). In addition, an elevated IL-23 concentration was
associated with women experiencing secondary infertility
rather than primary infertility (regardless of the cause of
infertility; adjusted r = 94.6pg/mL,P = 0.043).
3.2. Associations between Infertility Treatment Parameters and
Biomarker Levels in Follicular Fluid. A positive association
was determined to exist between the concentration of fol-
licular IL-12 and the number of fertilized oocytes (adjusted
r = 0.15pg/mL per every additional 2PN oocyte, P = 0.007)
and the proportion of good-quality embryos (adjusted r =
0.22pg/mL per every additional embryo, P = 0.006), when
the data were adjusted for age, cause of infertility, and fol-
licular size. Achieving intrauterine pregnancy was associated
with higher levels of follicular MIP-1β, as compared to hCG-
negative patients (adjusted for age and cause of infertility
r = 48.0pg/mL, P = 0.047). In addition, follicular MIP-
1β and IFN-α levels were both positively associated with the
diameter of a follicle (adjusted r = 7.8pg/mL,P = 0.037 and
r = 2.4pg/mL for every millimeter in diameter, P = 0.023,
resp.), regardless of age or cause of infertility.
The concentration of IL-8 in follicular ﬂuid was pos-
itively associated with intrauterine pregnancy (adjusted
for age, cause of infertility, rate of good-quality embryos
transferred,andendometrialthicknessr = 207.5pg/mL,P =
0.051), and also with parity (adjusted for age and cause of
infertility r = 150.6pg/mL for every child born, P = 0.039).
Not surprisingly, IL-8 was also associated with higher levels
of serum progesterone after ovarian stimulation (adjusted
r = 4.7pg/mL,P = 0.031).
Follicular IL-18 levels appeared to be positively corre-
lated with several outcomes, including increased chance for
intrauterine pregnancy (adjusted for the cause of infertility
r = 71.6pg/mL, as compared to hCG-negative patients,
P = 0.054), number of fetuses detected by ultrasonography
(adjusted for age, cause of infertility, number of embryos
transferred, rate of good-quality embryos among them, and
endometrial thickness r = 67.2pg/mL for every additional
fetus, P = 0.020), and with increased parity (adjusted for age
and cause of infertility r = 60.7p g / m Lf o re v e ryc h i l dt og i v e
birth, P = 0.038). Interestingly, the levels of both follicular
IL-8 and IL-18 increased as follicles grew (adjusted for age
and cause of infertility r = 40.2pg/mL, P = 0.005, and
r = 13 .1pg/mL for every additional millimeter in diameter,
P = 0.022, resp.).
3.3. mRNA Analysis of the Measured Protein Transcripts from
MGC and CGC. Our mRNA expression analysis demon-
strated that most of the studied transcripts were more
abundantly expressed in MGC (Figure 2). G-CSF and sAPO-
1/Fas were not diﬀerentially expressed in the two cell types.
Both of the interferons examined were found to be more
highly expressed in CGC, although this result was not
statistically signiﬁcant (Table 4). When the abundance of
intracellular transcripts was analyzed, the mRNA levels were
found to diﬀer by several orders of magnitude and were
characterizedbysubstantialinterpatientvariability(Table 4).
4. Discussion
In the current study, we evaluated the expression of 16
diﬀerent biomarkers in the follicular ﬂuid of infertile
women by using multiplex assay from Bender MedSys-
tems. These biomarkers included Th1/proinﬂammatory and
anti-inﬂammatory cytokines, chemokines and antiapoptotic
biomarkers that had previously been implicated in ovarian
function by our previous study [7]. Ultimately, we foundClinical and Developmental Immunology 7
Table 4: Relative∗ mRNA abundance of measured proteins in cumulus and mural granulosa cells.
Biomarkers CGC ± SD MGC ± SD P value (paired t-test)
G-CSF 0.000216 ±0.000151 0.000207 ±0.000109 0.930
IL-1β 0.001025 ±0.000640 0.070199 ±0.108075 0.178
IL-6 0.000082 ±0.000059 0.003981 ±0.006412 0.209
IL-12A 0.000104 ±0.000047 0.000209 ±0.000083 0.022
IL-18 0.001506 ±0.000958 0.007472 ±0.002346 <0.001
IL-23A 0.000009 ±0.000004 0.000025 ±0.000014 0.016
IFN-α 0.000236 ±0.000186 0.000044 ±0.000021 0.127
IFN-γ 0.000064 ±0.000045 0.000027 ±0.000021 0.157
TNF-α 0.000133 ±0.000150 0.001899 ±0.002363 0.117
IL-8 0.022214 ±0.009590 0.487650 ±0.431439 0.045
MCP-1 0.003409 ±0.004521 0.008618 ±0.009842 0.239
MIP-1α 0.000015 ±0.000011 0.000451 ±0.000718 0.191
MIP-1β 0.001029 ±0.000864 0.055073 ±0.071566 0.122
RANTES 0.000650 ±0.000282 0.014258 ±0.021169 0.293
sAPO-1/FAS 0.000024 ±0.000014 0.000024 ±0.000016 0.979
CD44(v6) 0.000024 ±0.000006 0.000045 ±0.000028 0.158
∗As compared to the average of three housekeeping gene transcripts: beta actin, glyceraldehyde-3-phosphate dehydrogenase, and ribosomal protein RPL13A.
Abbreviations: CGC: cumulus granulosa cells; MGC: mural granulosa cells; SD: standard deviation.
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Figure 2: Diﬀerential expression of measured protein transcripts
in cumulus and mural granulosa cells. ∗ Diﬀerences in expression
were statistically signiﬁcant. CGC: cumulus granulosa cells, MGC:
mural granulosa cells.
that 12 of the 16 examined biomarkers were associated with
a cause of infertility or IVF treatment outcome.
The mammalian ovulation event can be considered
from the perspective of an inﬂammatory reaction, with
proinﬂammatory cytokines produced and functionally inter-
acting throughout the process [10]. For example, IL-1β
has been evidenced to participate in ovulation induction
by facilitating follicular rupture [27]. The fact that we
found lower values of IL-1β in TFI patients indicates that
impairment of folliculogenesis might have occurred and
contributed to the infertility of these women. IL-18 is
known to induce cytokines that are important for both
folliculogenesis and ovulation, including IL-1β,T N F - α,a n d
IFN-γ [28]. Our ﬁnding that levels of IL-18 were relatively
low in unexplained infertility patients might then reﬂect
an underlying perturbed immunological proﬁle for this
infertility cause. Importantly, IL-18 has been suggested to
favor ovarian folliculogenesis; a positive correlation has been
reportedbetweentheleveloffollicularIL-18andthenumber
of retrieved oocytes and implantation success in women
with diﬀerent etiologies of infertility [29, 30]. Our ﬁnding
that follicular growth positively correlates with IL-18 levels
indirectly supports the role of IL-18 in follicle maturation.
Furthermore, our ﬁnding that higher follicular IL-18 was
associated positively with parity indicates that this cytokine
may increase the chance for pregnancy.
The elevated levels of follicular IFN-γ found in our
group of endometriosis patients is in agreement with
previousresultsobtainedwithserumsamples[27].Increased
production of IFN-γ may reﬂect the immune system’s
eﬀorts to overcome apoptosis inhibition and to decrease cell
proliferation in the case of endometriosis [31]. Additionally,
while a temporary increase in the concentration of IFN-γ
seems to be essential for ovulation, IFN-γ levels that exceed
normal physiologic concentrations may inhibit ovulation
and contribute to early pregnancy loss [28]. IFN-α is
synthesized primarily in response to infection, but the IFN-
α signaling pathways have also been demonstrated to be
involved in reproduction processes, even in the absence
of detectable infection [12]. The fact that the group of
healthy women (with male factor infertility) in our study
possessed higher levels of IFN-α than did women with TFI
further supports a positive role for IFN-α in reproduction.
In addition, the positive correlation that was identiﬁed
between follicular IFN-α levels and follicular diameter was
in accordance with previous IFN-α data from preovulatory
granulosa cells [32].
We observed elevated levels of TNF-α in endometriosis
patients, as compared to TFI patients. It is possible that
this ﬁnding simply reﬂects increased TNF-α serum levels8 Clinical and Developmental Immunology
that had inﬁltrated into the follicular ﬂuid [33] or increased
secretion by granulosa cells induced by the inﬂammatory
pelvic milieu in endometriosis [34]. TFI patients’ expression
of follicular TNF-α has also been previously suggested to
be below the threshold of standard detection systems [6].
TNF-α in IVF has already been the subject of much study
by infertility researchers. Some authors have concluded that
follicular TNF-α might deteriorate the microenvironment in
the follicle, thereby negatively aﬀecting oocyte and embryo
quality [35]. Still others have proposed a positive role of
TNF-α regarding oocyte quality, and ovulation [36]. Overall,
the roles of TNF-α in female reproduction are likely to be
complex and dynamically involved in the diﬀerent stages of
folliculogenesis [37].
Previous studies examining IL-12 in the follicular ﬂuid
have yielded contradictory results. Nevertheless, a majority
of the ﬁndings have indicated that IL-12 is associated with
an e g a t i v ee ﬀect on folliculogenesis, oocyte quality and
implantation [9, 20, 38]. We failed to detect any correlation
between the follicular level of IL-12 and the pregnancy
outcomeofIVF.Nonetheless,therewasapositiveassociation
identiﬁed between IL-12 and the quality of oocytes and
embryos. Our results are similar to a study published by
Ostanin et al. [39], wherein the authors reported that
follicular concentration of IL-12 was elevated in women who
produced more high-quality oocytes. IL-12 is a Th1 cytokine
that can become cytotoxic at high levels. It is, therefore, not
unexpectedthathighconcentrationsofIL-12inthefollicular
ﬂuid might impair the natural process of folliculogenesis
and ovulation [38]. However, in the current study, the mean
concentration of IL-12 was found to be more than 10-fold
lower than that reported in studies that had concluded dele-
terious function of IL-12 on reproduction [9, 20, 38]. Thus,
we suggest a dose-dependent role for IL-12 in the follicles.
We also determined that endometriosis was associated
with increased levels of follicular IL-23. Given that IL-23 is
known to participate in autoimmune diseases by promoting
inﬂammation, a hallmark of endometriosis, this result was
not surprising. Impaired follicular ﬂuid microenvironment
characterizedbyelevatedinﬂammatorycytokinesmayinfact
be the cause for poor oocyte quality, which in turn could
lead to poor IVF outcome in patients with endometriosis
[19]. The detrimental eﬀect of IL-23 on fecundity is further
supported by our ﬁndings of higher levels of IL-23 in women
who smoked or who suﬀered from secondary infertility.
MIP-1α is a marker for ongoing acute or chronic inﬂam-
matory host responses [18, 40]. Dahm-K¨ ahler et al. [41]
failed to detect MIP-1α in follicular ﬂuids of unstimulated
menstrual cycles, leading to their conclusion that MIP-
1α is not produced under physiological conditions. Our
contradictory ﬁndings of elevated levels of MIP-1α in PCOS
patients may reﬂect a character of increased inﬂammation
in stressed ovaries. To date, very few studies have appeared
in the literature that investigate the function of MIP-
1β in female reproduction, although this chemokine has
been suggested to promote folliculogenesis and pregnancy
establishment [39]. Such a positive role was also supported
by our ﬁnding that higher follicular ﬂuid MIP-1β levels
correlated with follicular growth and achieving pregnancy.
The correlation of IL-8 concentration with follicular
growth is in accordance with previously reported results.
When taking into consideration that IL-8 has also been
detected in unstimulated cycles [38], the involvement of
this chemokine in the natural process of folliculogenesis
and ovulation can be assumed [42]. Moreover, a recent
study showed that lower serum levels of IL-8 correlated
with a higher risk for extrauterine pregnancy [43]. Thus,
our ﬁnding of higher follicular ﬂuid IL-8 in cases of
normal intrauterine pregnancy seems sensible. Nonetheless,
two previous studies demonstrated no correlations between
follicular ﬂuid IL-8 concentration and IVF cycle parameters
orpregnancyresults[38,42].Thediscrepantresultsobtained
fromthesestudiesandourowncouldbeduetodiﬀerencesin
sample sizes, patient groups examined, or detection methods
used; this issue needs further investigation.
sAPO-1/Fas mediates apoptosis inhibition, which is im-
portant in preventing oocytes from succumbing to atresia
during follicular maturation [21]. Increased sAPO-1/Fas
levels have also been associated with enhanced activity of
smoking-induced antiapoptotic signaling pathways in the
oral cavity, which leads to epithelial hyperplasia [44]. In
our study, we detected higher levels of sAPO-1/Fas in active
smokers. Thus, our ﬁndings suggest that a compensatory
increase of sAPO-1/Fas was established in the apoptosis-
favoured environment of the follicles in active smokers.
A similar eﬀect has also been proposed for CD44(v6) in
the ovary, where macrophage membrane-expressed CD44
protein has been shown to participates in clearance of
apoptotic granulosa cells [44, 45]. Our ﬁndings of lower
levels of CD44(v6) in unexplained infertility and higher
levels in PCOS and active smokers might reﬂect impaired
apoptosis mechanisms in the ovaries of these patients.
Considering that cytokines likely aﬀect ovarian function,
one could argue about the source of these immunomod-
ulatory factors in follicular ﬂuid. The ovulatory process is
comparable to a classical local inﬂammatory reaction, and
leukocytes have been shown to participate actively in the
cyclic events of the ovary [6]. However, it is unlikely that
migrating leukocytes producing proinﬂammatory cytokines
represent the principal mechanism by which ovarian fol-
liculogenesis is regulated [6]. Increased levels of serum-
derived cytokines in follicular ﬂuid have been demonstrated
in endometriosis [33]. In addition, upregulated expression
of proinﬂammatory cytokines by granulosa cells has been
detected in cases of infertility [7]. Here, we conﬁrmed our
previous ﬁndings from the Aﬀymetrix GeneChip platform
using real-time PCR analysis to monitor mRNA expression
in diﬀerent conditions of infertility, as compared to levels
expressed in conditions of normal fertility. To the best of
our knowledge, our results represent the ﬁrst description
of the human granulosa cell expression proﬁle of IL-12A,
IL-23A, IL-18, MIP-1α, MIP-1ß, IFN-α,I F N - γ, and sAPO-
1/FAS. MIP-1ß has been studied in the mouse cumulus-
oocyte complex, where its expression increased in response
to experimental exposure to hyaluronan fragments, and the
related signal was determined to be mediated by Toll-like
receptors [46]. On the other hand, luteinizing hormone
induction of IFN-α was shown in rats and determinedClinical and Developmental Immunology 9
to function as a modulator of steroidogenesis and MGC
diﬀerentiation [47]. It is well known that cytokines and
apoptosis networks functionally interact with one another in
a variety of mammalian, and human, tissues. Therefore, our
results also indicate a strong role of these proteins in human
follicular physiology.
In conclusion, we discovered that various infertility eti-
ologies are accompanied by distinct intrafollicular cytokine
proﬁles. Furthermore, some of the cytokines evaluated, such
as IL-12, were determined to inﬂuence oocyte fertilization
and embryo quality, while others, such as IL-18, IL-8, and
MIP-1β, were found to be correlated with successful preg-
nancy following IVF treatment. Collectively, these factors
appear to be promising prognostic markers for IVF success
and should be evaluated as such by future prospective
studies.
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